Research progress of non-invasive biomarkers for neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer
10.12354/j.issn.1000-8179.2025.20250133
- VernacularTitle:可切除非小细胞肺癌新辅助免疫化疗的非侵入性生物标志物研究进展
- Author:
Wang QILIANG
1
;
Liu YING
1
Author Information
1. 天津医科大学肿瘤医院放射科,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室(天津市 300060)
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer(NSCLC);
neoadjuvant immunotherapy;
hemic and immune systems;
radiomics;
prognosis
- From:
Chinese Journal of Clinical Oncology
2025;52(6):304-308
- CountryChina
- Language:Chinese
-
Abstract:
With the promising overall efficacy of immune checkpoint inhibitors in non-small cell lung cancer(NSCLC)cohorts,neoadjuvant immunochemotherapy(NAIC)has emerged as a crucial clinical treatment for reducing surgical risks,improving pathological responses,and enhancing postoperative survival prognosis for patients with stage Ⅱ-ⅢB resectable NSCLC.However,the efficacy of NAIC and patient sur-vival outcomes vary between studies.Given the limitations of tissue-based programmed cell death-ligand 1(PD-L1)expression and tumor mutation burden(TMB)in dynamically monitoring the therapeutic efficacy of NAIC,alternative non-invasive potential biomarkers based on peripheral blood and imaging have gained widespread attention.This review highlights the advances in potential biomarkers,including in-flammatory derivatives,T-lymphocyte subsets,cytokines from peripheral blood,and radiomic features derived from CT images,for predict-ing the therapeutic efficacy and survival outcomes of NAIC in patients with NSCLC.
